CVS Caremark®

|  |
| --- |
| Reference number(s) |
| 2089-A |

# Specialty Guideline Management Cystagon

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
| --- | --- |
| Cystagon | cysteamine bitartrate |

## Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### FDA-approved Indications1

Cystagon is indicated for the management of nephropathic cystinosis in children and adults.

All other indications are considered experimental/investigational and not medically necessary.

## Documentation

Submission of the following information is necessary to initiate the prior authorization review:

* Initial requests: assay detecting increased cystine concentration in leukocytes or genetic testing results supporting diagnosis.
* Continuation requests: lab results or chart notes documenting a positive response to therapy (e.g., improvement, stabilization, or slowing of disease progression for serum creatinine, calculated creatinine clearance, leukocyte cystine concentration, or maintained growth [height]).

## Prescriber Specialties

This medication must be prescribed by or in consultation with a physician who specializes in the treatment of metabolic disease and/or lysosomal storage disorders.

## Coverage Criteria

### Nephropathic cystinosis1

Authorization of 12 months may be granted for treatment of nephropathic cystinosis when all of the following criteria are met:

* Diagnosis of cystinosis was confirmed by the presence of increased cystine concentration in leukocytes or by genetic testing; and
* Member will not use Cystagon in combination with Procysbi.

## Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in the Coverage Criteria section who are responding to therapy (e.g., improvement, stabilization, or slowing of disease progression for serum creatinine, calculated creatinine clearance, leukocyte cystine concentration, or maintained growth [height]).

## References

1. Cystagon [package insert]. Morgantown, WV: Mylan Pharmaceuticals Inc.; August 2021.